<DOC>
	<DOCNO>NCT00967525</DOCNO>
	<brief_summary>In trial investigator seek determine injecting cord blood cell directly bone marrow ( intraosseous injection ) , rather infuse intravenously , improve engraftment . The rational hematopoietic stem cell ( HSCs ) infuse intravenously never reach bone marrow , get trap organ , lung , instead . The potential advantage intraosseous infusion suggest study rodent demonstrate HSC transplant cell dose limit intraosseous injection effective route administration . The safety intraosseous injection , general , underscored vast experience use intraosseous injection resuscitation critically ill child . The safety inject HSCs intraosseously demonstrate clinical trial transplant bone marrow cell . To safeguard problem might result , intraosseous infusion fails improve engraftment trial , investigator integrate recently introduce strategy prove improve engraftment-the transplantation two cord blood unit . Transplanting two unrelated cord blood unit intravenous infusion show improve engraftment ( although still room improvement ) . In trial one unit inject intraosseously unit infuse intravenously . This study conduct forerunner large , multi-center trial . The investigator intend enroll five patient 1-2 year .</brief_summary>
	<brief_title>Intraosseous Infusion Unrelated Cord Blood Grafts</brief_title>
	<detailed_description>Hematopoietic ( blood forming ) stem cell ( HSCs ) reside primarily bone marrow . Traditionally , HSCs obtain directly bone marrow . Transplants use cell obtain way refer bone marrow transplant . HSCs also circulate blood . Transplants use cell obtain blood child adult refer peripheral blood stem cell transplant . The blood fetuses especially rich HSCs cell easily collect birth placenta . Transplants use cell call cord blood transplant . Although HSCs collect various site , HSC transplant , regardless source , give recipient intravenous infusion . The transplanted HSCs migrate bone marrow . Over past ten year unrelated cord blood transplantation become accept alternative bone marrow transplantation . African-Americans minority , underrepresented National Marrow Donor Program , benefit particularly . In infant young child cord blood transplantation appear effective bone marrow transplantation . In old child , adolescent adult , however , cord blood transplantation effective , primarily cord blood unit provide insufficient number cell ensure prompt reliable engraftment ( `` take '' transplant cell recipient 's bone marrow ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Age 36 month 60 year old ( YO ) 2 . No prior autologous allogeneic transplant 3 . Karnofsky performance score Lansky PlayPerformance least 80 1 . Age &lt; 36 month &gt; 60 YO 2. creatinine clearance nuclear medicine GFR &lt; 50 mL/min 3. cardiac ejection fraction &lt; 50 % 4. bilirubin &gt; 2 × upper limit normal ALT &gt; 4 × upper limit normal unresolved venoocclusive disease 5 . Pulmonary carbon monoxide diffuse capacity ( DLCO ) , adjust Hgb &lt; 50 % 6 . Karnofsky performance score Lansky PlayPerformance Scale &lt; 80 7 . Uncontrolled viral , bacterial , fungal infection time study enrollment 8 . Seropositive HIV 9 . Availability willing well HLA match relate ( genotypically identical mismatch single allele antigen define type HLA A , B , C DRB1 locus ) donor 10 . Availability willing well HLA match unrelated ( allele match mismatch single allele define allele level type HLA A , B , C DRB1 locus ) adult blood marrow donor 11 . Availability umbilical cord blood unit , provide least 4/6 HLA match define ≥ 5.0 * 107 NC/Kg ( cryopreserved )</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>malignancy</keyword>
	<keyword>Undifferentiated leukemia</keyword>
	<keyword>High risk malignancy</keyword>
</DOC>